New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
05:25 EDTSNYSanofi announces dengue vaccine candidate Phase III study meets primary endpoint
Sanofi Pasteur, the vaccines division of Sanofi, announced that the first of two pivotal Phase III efficacy studies with its dengue vaccine candidate has achieved its primary clinical endpoint. The efficacy study showed a significant reduction of 56% of dengue disease cases. Initial safety data are consistent with the good safety profile observed in previous studies. Full analysis of the data will be undertaken in the coming weeks and reviewed by external experts prior to disclosure at an upcoming international scientific congress and publication in a peer-reviewed journal later this year. First available data demonstrated a 56% reduction of dengue disease cases in a study of more than 10,000 volunteers from Asia. Initial safety data are consistent with the good safety profile observed in previous studies.
News For SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
11:19 EDTSNYSanofi reportedly ready to make acquisitions in animal medicine, Bloomberg says
Subscribe for More Information
December 4, 2014
11:12 EDTSNYSanofi diabetes sales head left company, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use